About The Study: This quality improvement analysis of clinical trials for metastatic breast, lung, colon, pancreatic, and prostate cancers found that a large proportion of the U.S. population lived within 30 miles of a clinical trial site. This finding suggests that while many clinical trials are available, they are not evenly distributed across the country and may not be accessible to all individuals, particularly racial and ethnic minority individuals. This disparity in access to clinical trials raises important questions about equity and fairness in the distribution of health care resources and opportunities for treatment.
About The Study: This quality improvement analysis of clinical trials for metastatic breast, lung, colon, pancreatic, and prostate cancers found that a large proportion of the U.S. population lived within 30 miles of a clinical trial site. This finding suggests that while many clinical trials are available, they are not evenly distributed across the country and may not be accessible to all individuals, particularly racial and ethnic minority individuals. This disparity in access to clinical trials raises important questions about equity and fairness in the distribution of health care resources and opportunities for treatment.
Corresponding Author: To contact the corresponding author, Wade T. Swenson, M.D., M.P.H., M.B.A., email drswenson@lakewoodhealthsystem.com; wade@ruralcancer.org.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamaoncol.2024.1690)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA Oncology
Discover more from Science
Subscribe to get the latest posts sent to your email.
